Search for content, post, videos

SynAct Pharma’s CEO resigns with immediate effect

Jeppe Øvlesen has been appointed new CEO, succeeding Torbjørn Bjerke, effective immediately due to a disagreement over the company’s strategy.

The decision was reached following an extraordinary general meeting and after the first meeting by the new board of directors.

“It has been a pleasure supporting SynAct from both the board of directors and as CEO,” said Torbjørn Bjerke. “We may have disagreement over the development strategy, but we all agree that resomelagon has tremendous potential. I wish the new team best of luck.”

Jeppe Øvlesen

Jeppe Øvlesen, born 1962, has a commercial background and a deal-making track record, reports SynAct. He has more than 20 years of experience at the executive level and has been involved in a string of start-up companies, including Action Pharma, Perfusion Tech, CLC Bio, Cercare Medical, ChemoMetec, Cetrea, Monsenso, PNN Medical, Mindway, ResoTher Pharma, Go Pen, Neurescue and TXP Pharma. From 2015 to 2023 Øvlesen was the CEO of SynAct Pharma. Øvlesen has an MBA with a focus on leadership and finance from the University of Hartford, US. He is currently chairman in HG Energy Group A/S, Cercare Medical A/S, Go-Pen A/S, and Neurescue ApS, and is a board member in Perfusion Tech Aps, ResoTher Pharma Aps, Cereno Scientific and SynAct Pharma.

“SynAct and resomelagon have a bright future, and I am excited to lead the company once again during such an important time,” says Jeppe Øvlesen. “I understand there remains many questions about the company’s path forward. Once the strategy is ready, we will communicate our plans to the market. I want to thank Torbjørn for his contribution to the company over the past years.”

At the extraordinary general meeting held today, Anders Kronborg, Sten Scheibye, Sten Sørensen, and Jeppe Øvlesen was elected new members of the board. Anders Kronborg was elected chairman of the board of directors.

Photo of Torbjørn Bjerke, former CEO of SynAc Pharma